History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 2, 2009, Pages 176-181

  Ananthakrishnan, Ashwin N ^a   Issa, Mazen ^a   Beaulieu, Dawn B ^a   Skaros, Sue ^a   Knox, Josh F ^a   Lemke, Kathryn ^a   Emmons, Jeanne ^a   Lundeen, Sarah H ^a   Otterson, Mary F ^a   Binion, David G ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Colectomy; Hospitalization; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CIGARETTE SMOKING; COLON RESECTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; FORECASTING; HOSPITALIZATION; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 67649703547     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20639     Document Type: Article

References (40)

1. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28: 25-281, vii.
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369:1641-1657.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
5. Caprilli R, Viscido A, Latella G. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:92-101.
6. Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg. 2005;140:300-310.
7. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515.
8. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990;31:329-333.
9. Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg. 2003;186:514-518.
10. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
11. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-110.
12. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543-550.
13. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282.
14. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20-28.
15. Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol. 2008;6:145-158; quiz 124.
16. Yu ED, Shao Z, Shen B. Pouchitis. World J Gastroenterol. 2007;13: 5598-5604.
17. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
18. Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg. 2003; 238:229-234.
19. Casati J, Toner BB, de Rooy EC, et al. Concerns of patients with inflammatory bowel disease: a review of emerging themes. Dig Dis Sci. 200;45:26-31.
20. de Rooy EC, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. Am J Gastroenterol. 2001;96:1816-1821.
21. Maunder R, Toner B, de Rooy E, et al. Influence of sex and disease on illness-related concerns in inflammatory bowel disease. Can J Gastroenterol. 1999;13:728-732.
22. Maunder RG, de Rooy EC, Toner BB, et al. Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol. 1997;11:681- 685.
23. Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680-687 e1.
24. Metcalf AM. Elective and emergent operative management of ulcerative colitis. Surg Clin North Am. 2007;87:633- 641.
25. Roberts SE, Williams JG, Yeates D, et al. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ. 2007;335:1033.
26. Bernal I, Manosa M, Domenech E, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci. 2006;51: 1434-1438.
27. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-1087.
28. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-835.
29. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.
30. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041-1048.
31. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
32. Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: a preliminary study. Gut. 1975;16:579-84.
33. Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn's disease. Am J Gastroenterol. 2008;103:154-161.
34. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
35. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529-1535.
36. Sanderson JD, Parkes GC. Timing of surgery for inflammatory bowel disease. BMJ. 2007;335:1006.
37. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo- controlled study. Gastroenterology. 2005;128:1805-1811.
38. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
39. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5: 345-351.
40. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.